• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Intuitive da Vinci procedures increased 17% in 2024

Intuitive da Vinci procedures increased 17% in 2024

January 15, 2025 By Sean Whooley

Intuitive Surgical logoIntuitive (Nasdaq: ISRG) today announced preliminary fourth-quarter results that highlight significant da Vinci surgical robot procedure growth.

Shares of ISRG rose nearly 5% to $565 apiece in early-morning trading following the release of the preliminary results.

The Sunnyvale, California–based surgical robotics leader reported 17% growth in worldwide da Vinci procedures in 2024. For the fourth quarter, that growth totaled 18%. The company anticipates 13%-16% procedure volume growth for da Vinci in 2025 as well. da Vinci placements also increased by 11% compared to 2024 (1,526 vs. 1,370). The company says 362 of those placements were its latest-generation da Vinci 5 system.

Preliminary fourth-quarter 2024 revenue totaled $2.41 billion, marking a 25% increase compared to the same period a year ago. That also comes in ahead of Wall Street expectations of $2.2 billion in sales. Intuitive expects full-year 2024 revenues to total $8.35 billion — good for 17% growth compared to 2023.

The company reported 23% growth in instruments and accessories revenue, thanks to growth in da Vinci and Ion procedure volume.

Intuitive also highlighted that 2024 included no noticeable procedure volume disruptions due to COVID-19, an external factor that had previously affected procedure volumes since 2020. The company reported treatments for a large portion of patients in the backlog created by the pandemic as well. Therefore, it reports an immaterial impact of patient backlogs to procedure volumes in 2024.

“We are pleased with customer adoption of da Vinci 5, Ion, and SP during the quarter and full year,” Intuitive CEO Gary Guthart said. “We remain focused on delivering the goals we share with our customers, centered on improving patient outcomes.”

The analysts’ take on Intuitive’s preliminary Q4 results

BTIG analysts Ryan Zimmerman and Iseult McMahon maintained a “Buy” rating for Intuitive following the preliminary report.

They note that da Vinci 5 procedures came in ahead of Wall Street expectations, while the company’s guidance falls in line with expectations. The analysts also expect Intuitive to continue to raise that range higher over the course of 2025.

“Overall, we view results positively,” the analysts wrote. “We think [da Vinci 5] growth continues to pace well ahead of expectations.”

Filed Under: Business/Financial News, Featured, Health Technology, MassDevice Earnings Roundup, Robotic-Assisted, Surgical, Surgical Robotics, Wall Street Beat Tagged With: Intuitive, Intuitive Surgical

More recent news

  • Teleflex wins Breakthrough Device designation for Freesolve resorbable scaffold
  • FDA clears Solventum’s combo wound care platform following Acera acquisition
  • GE HealthCare begins new global partnerships to advance theranostic imaging technology
  • Siemens Healthineers, Nvidia launch radiotherapy AI collaboration
  • J&J, Medtronic present pulsed field ablation data from global real-world use

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy